Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;34(3):355-368.
doi: 10.1016/j.bpa.2020.06.005. Epub 2020 Jul 3.

The utilization of buprenorphine in chronic pain

Affiliations
Review

The utilization of buprenorphine in chronic pain

Ivan Urits et al. Best Pract Res Clin Anaesthesiol. 2020 Sep.

Abstract

Reclassification of chronic pain as a disease may be helpful because patients with chronic pain require significant treatment and rehabilitation with a clear diagnosis. This can help address critical factors including suffering, quality of life, participation, and with family and social life, which continue to become more important in evaluating the quality of the health care we give our patients today. During the past decade of the opioid epidemic, methadone was the primary treatment for opioid addiction until buprenorphine was approved. Buprenorphine's high-affinity partial agonist properties make it a good alternative to methadone due to lower abuse potential and safer adverse effect profile while maintaining significant efficacy. Expanded out-patient prescribing options have allowed physician and physician extenders such as physician assistants and nurse practitioners to treat these patients that otherwise would have been required to utilize methadone. With unique pharmacological properties, buprenorphine is a safe and effective analgesic for chronic pain. The literature for buprenorphine shows great potential for its utilization in the treatment of chronic pain.

Keywords: buprenorphine; chronic pain; opioids; pain control; partial agonist.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors of this manuscript have no conflicts of interest to disclose.

MeSH terms

LinkOut - more resources